AP20ROSETULINO 64 APR 2006

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	s :	Merck & Co., Inc.	
Int'l Applr No.	n. :	PCT/US2004/035112	
Int'l Date Filed	:	20 October 2004 (10/20/2	004)
Serial No.	:	(To be assigned)	Case No.: 21179Y
Filed	: .	April 4, 2006	
For	:	WITH A DIPEPTIDYL P	ROWTH HORMONE LEVELS EPTIDASE IV INHIBITOR MONE SECRETAGOGUE
Commissioner for Patents Alexandria, Virginia 22313-1450			

PRELIMINARY AMENDMENT

Sir:

The above-identified case is a PCT application entering the US National Phase under 35 U.S.C. § 371 and Article 39(1)(a) of the Patent Cooperation Treaty. Applicants respectfully request entry of the following amendments prior to prosecution of the subject application. Any additional fees associated with this Amendment may be charged to Merck Deposit Account No. 13-2755.

Please amend this application as follows:

Amendments to the Specification are reflected on page 2 of this response.

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this response. Remarks begin on page 5 of this response.